Advice
Product overview
Product overview
The content of this evidence summary was up-to-date in July 2020. See summaries of product characteristics (SPCs), British National Formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information.
Remsima for subcutaneous injection (Celltrion Healthcare Hungary Kft) is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)‑alpha. It has a marketing authorisation for managing rheumatoid arthritis in combination with methotrexate.